This study investigates multiple myeloma. It focuses on understanding the biological and test clinical factors that affect how the disease progresses, relapses, and resists treatment.
The study evaluates the integration of clinical information with advanced genomic and molecular analyses to identify features linked to therapy response and disease behavior.
- Who can participate: Adults aged 18 and older with a diagnosis of monoclonal gammopathy or active multiple myeloma are eligible to participate. Participants must provide informed consent for study participation and data processing.
- Study details: Participants will have their clinical data integrated with genomic and molecular analyses, including sequencing and tumor markers evaluation. All data is securely stored to maintain confidentiality.
How understandable was the trial content above?
Hard to understand
Easy to understand